Role of the combined use of clinical stage, serum PSA and Gleason score for the improvement of preoperative staging of prostate cancer
https://doi.org/10.17650/1726-9776-2008-4-2-48-52
Abstract
Objective. To improve prediction accuracy of non-organ confined prostate cancer before radical prostatectomy.
Material and methods. Diagnostic efficacy of clinical staging, pretreatment PSA, Gleason score in prostate biopsy and combination of aforementioned factors in prediction or capsular penetration or seminal vesicle invasion were assessed in 272 pts. undergone radical prostatectomy in RIOMR between 1996 and 2007. Sensitivity, specificity and diagnostic accuracy of these factors were compared. Receiver-OperatingCharacteristic (ROC) curves were constructed and areas under curves were calculated.
Results. Sensitivity, specificity and diagnostic accuracy for clinical staging were 39,3%, 88,1% and 68,0%; for Gleason score 7—10 — 41,1%, 80,6%—64,3%; for pretreatment PSA≥20 ng/ml — 45,5%, 80,6%—66,2% accordingly; for only 1 aforementioned factor — 78,6%, 58,1% and 66,5%; for combination of 2 factors — 39,3%, 92,5% and 70,6%; for 3 — 5,4%, 98,2% and 42,7% accordingly. Areas under ROC curves for clinical stage, Gleason score, pretreatment PSA and combination of aforementioned factors were 0,66 (95%CI 0,60 — 0,73); 0,64 (95%CI 0,57 — 0,71); 0,69 (95%CI 0,63 — 0,76) and 0,74 (95%CI 0,68 — 0,80).
Conclusion. Diagnostic accuracy for combination of clinical stage, Gleason score and pretreatment PSA was highest comparing to use of these single variables. Presence of 0 to 1 unfavorable factors may be used as an indication for radical prostatectomy according to our data.
About the Authors
O. G. Sukonko
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
A. I. Rolevich
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
S. L. Polyakov
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
S. A. Krasny
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
A. V. Poluyanchik
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
T. I. Nabebina
N.N. Alexandrov Institute of Oncology and Medical Radiology
Belarus
Minsk
Belarus
Minsk
References
1. Thompson I., Thrasher J.B., Aus G. and Prostate Cancer Clinical Guideline Update Panel. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. J Urol 2007;177:2106—31.
2. Hittelman A.B., Purohia R.S., Kane C.J. Update of staging and risk assessment for prostate cancer patients. Curr Opin Urol 2004;14:163—70.
3. Stephenson A.J., Kattan M.W. Nomograms for prostate cancer. BJU Int 2006;98:39—46.
4. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582—93.
5. Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110—14.
6. Angulo J.C., Montie J.E., Bukowsky T. et al. Interobserver consistency of digital rectal examination in clinical staging of localized prostatic carcinoma. Urol Oncol 1995;1:199—205.
7. Santucci R.A., Brawer M.K. Correlation of prostate-specific antigen and ultrasonography in the evaluation of patients with carcinoma of the prostate. Semin Urol 1994;12:252—64.
8. Yu K.K., Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59—85.
9. Smith J.A. Jr., Scardino P.T., Resnick M.I. et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997;157:902—6.
10. Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909—16.
11. Oesterling J.E., Chan D.W., Epstein J.I. et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766—72.
12. Partin A.W., Carter H.B., Chan D.W. et al. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747—52.
13. Stamey T.A., Caldwell M., McNeal J.E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297—301.
14. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58—64.
15. Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445—51.
16. Blute M.L., Bergstralh E.J., Partin A.W. et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591—5.
17. Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843—8.
18. Поляков С.М., Левин Л.Ф., Шебеко Н.Г. Злокачественные новообразования в Беларуси, 1996–2005. Под ред. А.А. Граковича, И.В. Залуцкого. Минск, БелЦМТ; 2006.
Review
For citations:
Sukonko O.G., Rolevich A.I., Polyakov S.L., Krasny S.A., Poluyanchik A.V., Nabebina T.I. Role of the combined use of clinical stage, serum PSA and Gleason score for the improvement of preoperative staging of prostate cancer. Cancer Urology. 2008;4(2):48-52. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-2-48-52
Views:
246
Email this article 